Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Cagrilintide for Sale > Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide
Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide buy - large image1
Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide buy - image1
Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide buy - image2
Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide buy - image3
Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide buy - image4
Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide buy - image5
Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide buy - image6

Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide

66 Inquiries

Unit Price:

$100-110/UNIT FOB

Get Latest Price
CAS No.:

1415456-99-3

Grade:

Industrial Grade

Content:

99.9%

Port:

广州

Packaging:

2.5kg/box

Price valid (until):

2026-12-31

Company Type:
Trader
Location:
China
Qualification:
Main Products:

Retatrutide raw,Tirzepatide raw,TB500 raw

  • Product Description

  • Seller Information

  • Inquiry History

  • Description

    If needed, please add me on WhatsApp at +852 5487 8366 and I’ll send you our product price list. Or contact me via email at 2131997166@qq.com.

    Unlock Synergistic Weight Control and Metabolic Balance with Advanced Cagri Peptide

      Cagrilintide (Cagri) is a next-generation amylin analogue that works in harmony with the body's natural satiety signals to promote profound weight loss and metabolic health. By mimicking the action of amylin—a hormone co-secreted with insulin—Cagri slows gastric emptying, reduces appetite, and enhances the feeling of fullness after meals. This peptide also modulates glucagon secretion, helping to stabilise blood glucose levels without causing hypoglycaemia. Clinical studies have demonstrated that Cagri, when used as part of a comprehensive plan, can lead to significant reductions in body weight and waist circumference, outperforming many traditional approaches.

    Shop Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide-Detailed Image 1

     Its unique mechanism targets both central and peripheral pathways, making it an ideal companion for those struggling with obesity or weight-related comorbidities. Unlike single-action agents, Cagri addresses the multifaceted nature of appetite regulation, offering a sustainable path to healthier living. Users often report reduced food cravings, improved eating patterns, and a renewed sense of control over their dietary choices. The peptide is also well-tolerated, with most individuals experiencing only mild, transient effects that diminish over time.

    Shop Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide-Detailed Image 2
    Shop Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide-Detailed Image 3

     Cagri represents a breakthrough in the field of metabolic medicine, providing a safe and effective tool for long-term weight management. Its compatibility with other metabolic agents further enhances its versatility, allowing for personalised regimens that maximise results. Whether you are starting your weight-loss journey or seeking to overcome a plateau, Cagri offers the support you need. Embrace this innovative peptide and take a confident step toward a lighter, healthier future.



    Shop Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide-Detailed Image 4
    Shop Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide-Detailed Image 5
    Shop Explore Amylin Receptor Metabolic Pathways with Research-Grade Cagrilintide Peptide-Detailed Image 6
    ECHEMI Editorial Reference

    Cagrilintide is a long-acting amylin analog and peptide-based pharmaceutical ingredient. As a pharmaceutical raw material, Cagrilintide is characterized by its peptide structure and amylin receptor activity. It is suitable for API research, analytical testing, pharmaceutical development, and related manufacturing processes.

    Basic Info
    Product Name:

    Cagrilintide

    Other Name:

    ‌Cagrilitide、Cagrilintide acetate、Caglitide、Kagliptin、Cargliptin、Cargilinitide

    CAS No.:

    1415456-99-3

    Molecular Formula:

    C194H312N54O59S2

    Molecular Weight:

    0

    EC Number:

    206-141-6

    Color/Form:

    White to off-white

    Research
    Class:

    Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)

    Status:

    Investigational — Phase 3 (REDEFINE program, CagriSema combination)

    Mechanism:

    A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity.

    Activity note:

    Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.

    Source:

    MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.

    Clinical Development:

    NCT05249895; NCT05249882

    References
    PubChem:

    PubChem

    Disclaimer:

    Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Retatrutide raw,Tirzepatide raw,TB500 raw

    Location:

    Room 402, Unit 2, Building 23, Dalutou Village, Jiangdong Sub-district, Yiwu City, Jinhua City, Zhejiang Province (Self-declared)

    Year of Establishment:

    2025

    Established in 2025, Yiwu Weide Trading Company specializes in the research, development, production, and sales of peptide products, synthetic peptide amino acids, beauty and weight-loss products, and raw materials for cosmetics designed to reduce dark spots. The company possesses strong R&D capabilities, sophisticated synthesis technologies, and advanced quality control methods. It actively collaborates with major enterprises and manufacturers, adhering to the philosophy of industrial development to serve society and its customers. The company consistently prioritizes market demand, continuously developing high-tech beauty peptides for spot removal and wrinkle reduction. Its products are primarily exported to the United States, Europe, South Africa, Nigeria, and other countries and regions. With extensive export experience, the company ensures the safe delivery of its shipments.

  • Inquiry History
    66 Inquiries
    Country Product Purchase Quantity Date Posted
    United States

    Cagrilintide

    20 MG Sep 30, 2026
    Australia

    Cagrilintide

    20 MG Aug 17, 2026
    United Kingdom

    Cagrilintide

    10 MG Jul 31, 2026
    France

    Cagrilintide

    10 MG May 22, 2026
    Australia

    Cagrilintide

    4 MT Mar 9, 2026
    United States

    Cagrilintide

    15 MG Feb 25, 2026
    United States

    Cagrilintide

    10 PCS Dec 27, 2025
    United States

    Cagrilintide

    2 MT Dec 21, 2025
    United States

    Cagrilintide

    100 MG Oct 28, 2025
    United States

    cagrilintide

    2 MT Aug 8, 2025
    Philippines

    Retatrutide

    5 MG Aug 5, 2025
    China

    Cagrilintide

    100 G May 6, 2025
    United States

    cagrilintide

    5 MG Feb 18, 2025
    United States

    Cagrilintide

    3 MT Feb 7, 2025
    United States

    Cagrilintide

    100  Nov 12, 2024
    United States

    Cagrillintide Lyophilized powder

    100 MG Jul 4, 2024
    United States

    Cagrillintide Lyophilized powder

    1000 MG Apr 20, 2024
    United States

    Cagrilintide

    10 MG Sep 23, 2026
    United States

    Cagrilintide

    25 MG Aug 31, 2026
    United States

    Cagrlintide

    1 MT Jul 31, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.